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Abstract
Background:  There is increasing evidence indicating that genes involved in certain metabolic processes of
cardiovascular diseases may be of particular influence in people with low body weight at birth. We examined whether
the apolipoprotein (APO) E, APOC3 and the peroxisome proliferator-activated receptor-γ-2 (PPARγ2) polymorphisms
influence the association between low birth weight and blood lipid levels in healthy adolescents aged 13–18.5 years.
Methods: A cross-sectional study of 502 Spanish adolescents born at term was conducted. Total (TC) and high density
lipoprotein cholesterol (HDLc), triglycerides (TG), apolipoprotein (apo) A and B, and lipoprotein(a) [Lp(a)] were
measured. Low density lipoprotein cholesterol (LDLc), TC-HDLc, TC/HDLc and apoB/apoA were calculated.
Results: Low birth weight was associated with higher levels of TC, LDLc, apoB, Lp(a), TC-HDLc, TC/HDLc and apoB/
apoA in males with the APOE ε3ε4 genotype, whereas in females, it was associated with lower HDLc and higher TG
levels. In males with the APOC3 S1/S2 genotype, low birth weight was associated with lower apoA and higher Lp(a), yet
this association was not observed in females. There were no associations between low birth weight and blood lipids in
any of the PPARγ2 genotypes.
Conclusion: The results indicate that low birth weight has a deleterious influence on lipid profile particularly in
adolescents with the APOE ε3/ε4 genotype. These findings suggest that intrauterine environment interact with the
genetic background affecting the lipid profile in later life.
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Background
There is increasing evidence indicating that low birth
weight is a risk factor for cardiovascular disease. Indeed,
among persons born at term, those with lower birth
weights have a higher relative risk of metabolic health
problems in early adulthood, including hypertension, car-
diovascular disease, and type 2 diabetes [1]. In this con-
text, findings from the AVENA Study (Alimentación y
Valoración del Estado Nutricional en Adolescentes, Food and
Nutritional Status in Spanish Adolescents) indicated that
birth weight is associated with a number of cardiovascular
disease risk factors in adolescents such as total and central
body fat, fat free mass, and muscular fitness [2-5].
One of the hypotheses explaining this phenomenon is the
predisposition to adopt a "thrifty phenotype". According
to this theory, fetal adaptation to an adverse intrauterine
environment involves programming of pathways that
might predispose to metabolic abnormalities and cardio-
vascular disease in later life. The intra-uterine under- or
over-nutrition can alter the gene expression of the fetus,
causing developmental adaptations that may lead to per-
manent changes in physiology and metabolism; changes
that may have consequences later in life.
Findings of several cohort studies indicate that low birth
weight is associated with adverse plasma lipid profile [6-
8], whereas others have suggested that this association is
too small to be considered of public health importance
and that other variables as postnatal weight gain could act
as confounder of this relationship [9]. One would predict
that genes involved in the metabolic processes of these
diseases may have different effects on people with differ-
ent body weight at birth. This phenomenon has been
described in relation to blood lipids and the apolipopro-
tein (APO) E gene [10], and both blood lipids and insulin
resistance and the peroxisome proliferator-activated
receptor-γ-2 (PPARγ2) gene [11,12]. We have studied the
effect of the Ala12 allele in the PPARγ2 gene on the rela-
tionship between birth weight and body composition in
Spanish adolescents, and we showed that small body
weight at birth may program lower fat free mass in adoles-
cents carrying the Ala12 allele [13].
Coronary heart disease is a leading cause of global mortal-
ity. The relationship between blood lipids and the devel-
opment of coronary heart disease in children and
adolescents is well established. Results from the AVENA
Study showed that 20–30% of Spanish adolescents
present an unfavorable blood lipid profile [14,15]. In the
AVENA study, the APOE, APOC3 and PPARγ2 gene poly-
morphisms were genotyped. The ApoE gene is one of the
most important genetic determinants of atherogenesis,
since its major function is to regulate the hepatic clearance
of triglycerides (TG) rich particles such as chylomicron
remnants and very low density lipoprotein remnants. The
APOC3 gene have also been proposed as being potentially
responsible for the occurrence of lipid profile distur-
bances, since it has an inhibitory effect on lipoprotein
lipase activity and hepatic uptake of lipoproteins [16].
Finally, the PPARγ-2 has been shown to enhance lipopro-
tein TG hydrolysis by endothelial lipoprotein lipase,
which in turn seems to affect lipid profile [17].
To understand whether an adverse intrauterine environ-
ment may alter the expression of these cardiovascular dis-
ease-related genes is clinically relevant. This study aims to
clarify to what extent variants of these genes might interact
with birth weight in determining the blood lipid profile
later in life. Therefore, we examined the influence of
APOE, APOC3 and PPARγ2 gene polymorphisms on the
association between low birth weight and blood lipid lev-
els in Spanish adolescents from the AVENA Study.
Methods
The AVENA Study is a cross-sectional study designed to
assess the nutritional status of a representative sample of
Spanish adolescents aged 13 to 18.5 years. Data collection
took place from 2000 to 2002 in five Spanish cities
(Madrid, Murcia, Granada, Santander and Zaragoza). The
complete methodology of the study has been described in
detail elsewhere [15,18]. The number of adolescents
included in the AVENA Study was 2859 adolescents.
Blood samples and DNA data were randomly obtained
from 502 participants. The subgroup from which blood
samples were obtained was similar to the remaining sub-
jects regarding the variable selected to calculate the
number of participants to be included in the study, i.e.
body mass index (BMI) [15], as well as regarding age (P =
0.750) and gender proportions (P = 0.320). A comprehen-
sive verbal description of the nature and purpose of the
study was given to the adolescents, their parents and
teachers. Written consent to participate was requested
from both parents and adolescents. Adolescents with per-
sonal history of cardiovascular disease, under medication
at the time of the study, or those who were pregnant, were
excluded. The study protocol was performed in accord-
ance with the ethical standards laid down in the 1961
Declaration of Helsinki (as revised in Hong-Kong in 1989,
and in Edinburgh in 2000), and approved by the Review
Committee for Research Involving Human Subjects of the
Hospital Universitario Marqués de Valdecilla (Santander,
Spain).
Before any testing was performed, the parents completed
a questionnaire, part of which addressed the adolescents'
previous and current health status. Socioeconomic status
was also assessed via the questionnaire, and was defined
by the educational level and occupation of the father.
According to this information, and following the recom-BMC Medical Genetics 2008, 9:98 http://www.biomedcentral.com/1471-2350/9/98
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mendation of the Spanish Society for Epidemiology, the
adolescents were classified into five categories: low (I),
medium-low (II), medium (III), medium-high (IV) and
high socioeconomic status (V).
Neonatal data
Data on birth weight and gestational age at birth were
obtained from health booklets records that are issued at
birth and where child's paediatricians records birth
weight, charts the infant's growth and vaccinations. Birth
weight was expressed as the standard deviation from the
expected weight calculated with the use of reference stand-
ards previously described for this population, according
to sex and gestational age [19]. This variable (called birth
weight score) will be used for the analyses.
Gestational age was coded as 1 for those who were born
between the 35th to 40th week of gestation, and 2 for those
who were born after the 40th week of gestation. According
to this information, 80.9% and 77.0% of males and
females, respectively, were born between 35 to 40 weeks
of gestation, and 12.2% of males and 15.1% of females
were born after more than 40 weeks of gestation. The per-
centage of adolescents born before 35 weeks of gestation
was 6.9% of the males and 7.9% of the females. This
group was not included in the analyses.
Physical examination
Anthropometric measurements were obtained as
described elsewhere [20,21]. BMI was calculated as weight
in kilograms divided by square of height in meters (kg/
m2). Skinfold thickness was measured at the biceps, tri-
ceps, subscapular, suprailiac, thigh and calf on the left side
of the body to the nearest 0.2 mm using a Holtain skin-
fold caliper. Body fat percentage was calculated from skin-
fold thicknesses (triceps and subscapular) using
Slaughter's equations [22], and fat free mass (kg) was
derived by subtracting fat mass from total body weight.
Reference values for anthropometric measurements of the
AVENA Study can be found elsewhere [20,21].
Identification of pubertal development was assessed
according to Tanner & Whitehouse [23]. Self-reported
genital development in males and breast development in
females were used for pubertal stage classification.
Cardiorespiratory fitness
Cardiorespiratory fitness was assessed by the 20 m shuttle
run test as previously described [24]. It was considered as
the number of stages completed (precision of 0.5 steps).
All participants were familiarized with the test, since the
20 m shuttle run test is one of the fitness tests included in
the physical education curriculum in our country. Refer-
ence values of fitness levels have been reported for the
whole study population as well as for those adolescents
from whom blood sample was obtained [25].
Blood sampling
Blood (20 ml) was collected from an antecubital vein
between 8:00 and 9:00 a.m, after an overnight fast. Serum
levels of total (TC) and high density lipoprotein choles-
terol (HDLc), as well as the levels of TG, apolipoprotein
(apo)A and B, and lipoprotein(a) [Lp(a)] were measured.
The coefficients of variation were less than 3% and the
intra-class coefficients were higher than 0.96% for all
blood variables. Quality control of the assays was assured
by the Regional Health Authority, as is compulsory for all
hospital clinical laboratories in Spain.
Low density lipoprotein cholesterol (LDLc) was calcu-
lated with the Friedewald formula [26]. The following
atherogenic indices were also calculated: TC-HDLc, TC/
HDLc, and apoB/apoA. A detailed description of the
blood analysis as well as reference values for lipid and
lipoprotein has been reported by Ruiz et al. [15,27].
Genotyping
Genomic DNA was extracted and purified from 500 μL of
whole blood treated with EDTA, using the Quiagen proce-
dure described by Higuchi [28]. APOE genotypes were
determined by polymerase chain reaction (PCR) and
allele-specific restriction digestion of the amplified prod-
ucts with the restriction enzyme HhaI, as described else-
where [29] (rs7412, and rs429358). APOE genotypes were
encoded as 1 = ε2/ε3, 2 = ε3/ε3, and 3 = ε3/ε4. APOC3
genotypes were determined by PCR and allele-specific
restriction digestion of the amplified products with the
restriction enzyme SstI following the procedures
described elsewhere [30]. APOC3 genotypes were
encoded as 1 = S1/S1 and 2 = S1/S2 (rs5128). The PPARγ2
genotypes were determined by the PCR method and fur-
ther digestion of products with BstU-I restriction enzymes
as previously described [31], and were encoded as 1 =
Pro12/Pro, and 2 = Pro12/Ala and Ala12/Ala genotype
[32] (rs1801282). The percentage of adolescents with the
Ala12/Ala genotype was 1.3%, therefore this sub-group
was analyzed together with the Pro12/Ala.
Statistical analysis
Following a bivariate correlation analysis, multiple regres-
sions were used to study the association between birth
weight and blood lipid levels, for males and females sep-
arately (unadjusted model). Further analyses were done
after controlling for age, pubertal stage, socioeconomic
status, gestational age, BMI and cardiorespiratory fitness
(adjusted model). A separate regression model was per-
formed for each lipid parameter. Additional analyses were
also performed by genotypes.BMC Medical Genetics 2008, 9:98 http://www.biomedcentral.com/1471-2350/9/98
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To stabilize variability and to achieve normality in the
residuals, TC, HDLc, LDLc, TG, apoA, apoB and Lp(a)
were transformed to the natural logarithm.
The impact on blood lipid levels of APOE, APOC3 and
PPARγ2 genotypes was analyzed by one-way analysis of
variance (ANOVA), for males and females separately. For
the APOE genotypes, the subgroup means were compared
by Tukey's test. Comparisons were adjusted for mass sig-
nificance as described by Holm [33,34]. The method of
Holm proceeds as follows: Sort the P-values of the k tests
in increasing order, P1, P2, ..., Pi, ..., Pk. If P1 > α/k; none of
the k tests are significant, and the test procedure is fin-
ished. If P1 ≤ α/k, test 1 is significant, and now P2 is exam-
ined. If P2 > α/(k - 1), none of the (k - 1) remaining tests
are significant, but if P2 ≤ α/(k - 1), test 2 is significant and
P3 is examined. This procedure goes on until Pi > α/(k - i +
1), and the procedure is interrupted. This method keeps
family error rate less than α. Family error rate is defined as
the probability that one or more false significances out of
k tests is less than or equal to α.
Interaction effects between birth weight and sex, and
between birth weight and genotypes were tested by insert-
ing product terms for the relevant variables. The analyses
were performed using the Statistical Package for Social Sci-
ences (SPSS, v. 15.0 for WINDOWS; SPSS Inc, Chicago)
and the level of significance was set to 0.05.
Results
Descriptive characteristics of the study sample are shown in
Table 1.
Interactions
There was a significant (all P < 0.05) interaction effect
between birth weight and sex in all the outcome variables,
therefore, all the analyses were performed separately for
males and females. There was a significant interaction
effect between birth weight and APOE in all of the out-
come variables (TC, P = 0.02; HDL, P = 0.021; LDLc, P =
0.001; apoA, P = 0.049; apoB, P = 0.01; Lp(a), P = 0.051;
TC-HDLc, P = 0.025; apoB/apoA, P = 0.054), except for TG
(P = 0.362). There was also a significant interaction effect
between birth weight and APOC3 (for TG, P = 0.025;
apoA, P = 0.038, and Lp(a), P = 0.002). No significant (all
P > 0.1) interaction effect between birth weight and
PPARγ2 was found.
Birth weight and lipids
In males, low birth weight was associated with lower lev-
els of HDLc and apoA, and higher TC/HDLc and apoB/
apoA ratios (Figure 1). Birth weight was not significantly
associated with blood lipids in females. The results were
similar after controlling for age, pubertal stage, socioeco-
nomic status, gestational age, BMI and cardiorespiratory
fitness (Table 2).
Table 1: Descriptive characteristics of the study sample
Males (n = 260) Females (n = 242)
Age (years) 15.4 ± 1.4 15.4 ± 1.4
Tanner II,III,IV,V (%) 5.8, 15.1, 41.8, 37.3 1.6, 8.1, 54.3, 36.0
Weight (kg) 64.6 ± 13.4 56.8 ± 10.5
Height (cm) 170.7 ± 8.2 161.5 ± 6.4
Body mass index (kg/m2) 22.1 ± 3.9 21.7 ± 3.5
Cardiorespiratory fitness (stage) 7.0 ± 2.6 4.1 ± 1.8
Sum of 6 skinfolds 75.8 ± 38.1 98.8 ± 31.9
Percentage body fat 20.2 ± 10.4 25.6 ± 6.6
Triglycerides (mg/dl) 71.3 ± 31.6 64.7 ± 26.4
TC (mg/dl) 156.7 ± 26.4 169.9 ± 26.4
HDLc (mg/dl) 51.0 ± 9.7 59.2 ± 11.6
LDLc (mg/dl) 91.4 ± 23.9 97.4 ± 23.2
ApoA (mg/dl) 116.9 ± 17.1 127.7 ± 19.2
ApoB (mg/dl) 66.9 ± 14.3 69.9 ± 13.8
Lp(a) (mg/dl)* 14.1 ± 4.2 5.3 ± 3.9
ApoA/ApoB (mg/dl) 1.8 ± 0.5 1.9 ± 0.5
TC-HDLc (mg/dl) 105.7 ± 25.9 110.6 ± 25.8
Birth weight (g) 3443.0 ± 539.0 3283 ± 564
Birth weight score 409.0 ± 516.0 353 ± 559
Socieconomic status I,II,III,IV,V (%) 5.9, 25.3, 41.6, 23.6, 3.6 7.2, 25.4, 37.1, 23.3, 6.9
Values are means ± SD, otherwise indicated.
TC indicates total cholesterol; HDLc, high density liprotein cholesterol; LDLc, low density lipoprotein cholesterol; TG, triglycerides; Apo, 
apolipoprotein; Lp(a), lipoprotein a.
*Geometric mean ± SD.BMC Medical Genetics 2008, 9:98 http://www.biomedcentral.com/1471-2350/9/98
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Genotypes and lipids
All the genotype frequencies of the analyzed gene poly-
morphism were in agreement with the Hardy-Weinberg
equilibrium. The distribution of the APOE genotypes did
not differ between males and females (P = 0.961) (Table
3). Males with the ε2ε3 genotype had lower levels of TC,
LDLc and apoB compared with those with the ε3ε3 geno-
type. Similarly, females with the ε2ε3 genotype had lower
levels of LDLc, and apoB compared with those with the
ε3ε3 genotype. Females with ε2ε3 genotype had higher
levels of apoA compared with those with the ε3ε3 geno-
type. There were no subjects with the ε2ε2, ε2ε4 or the
ε4ε4 genotype.
The distribution of the APOC3 genotypes did not differ
between males and females (P = 0.489) (Table 4). In
males, levels of blood lipid were similar between S1/S1
and S1/S2 genotypes, whereas in females, adolescents
with the S1/S1 genotype had lower levels of TC and TC-
HCLc compared with those with the S1/S2 genotype.
The distribution of the PPARγ2 genotypes did not differ
between males and females (Pro12/Pro, 85 and 82% in
males and females, respectively; Pro12/Ala, 15 and 18%,
in males and females, respectively). No differences were
found between the Pro12/Pro and Pro12/Ala12 genotypes
in any of the lipid parameters studied, nor in BMI (data
not shown).
There were no differences between all the genotypes in
birth weight in males and females. The outcome did not
change when all the analyses were adjusted for age and/or
pubertal development.
Birth weight, lipids and genotype interactions
Low birth weight was associated with higher levels of TC,
LDLc, apoB, Lp(a), TC-HDLc, TC/HDLc and apoB/apoA
in males with the APOE ε3ε4 genotype, after controlling
for age, pubertal status, socioeconomic status, gestational
age, BMI and cardiorespiratory fitness (Table 5). Low birth
weight was also associated with lower levels of HDLc and
apoA in males with the APOE ε3ε3 genotype. In females
with the APOE ε3ε4 genotype, low birth weight was asso-
ciated with lower levels of HDLc and higher levels of TG.
Low birth weight was not significantly associated with any
of the lipid parameters studied in those adolescents with
the APOE ε2ε3 or in females with the ε3ε3 genotype.
Low birth weight was associated with lower levels of apoA
in males with the APOC3 S1/S1 genotype, and higher lev-
els of Lp(a) in those with both the APOC3 S1/S1 and the
S1/S2 genotype. In females, low birth weight was not sig-
nificantly associated with blood lipids in any of the
APOC3 genotypes (Table 6). There were no associations
between low birth weight and blood lipids in any of the
PPARγ2 genotypes (data not shown). The outcome did
not change when BMI was not included in the model. The
results did not materially change either when another
anthropometric index (i.e. sum of six skinfold thick-
nesses, percentage of body fat, fat free mass, waist circum-
ference, height squared) rather than BMI was included in
the model.
Discussion
The results of the present study show that low birth weight
seems to have a deleterious influence on blood lipid pro-
file, particularly in those adolescents with the APOE ε3/ε4
genotype. The results also suggest that low birth weight is
associated with lower levels of HDLc and apoA, and
higher TC/HDLc and apoB/apoA ratios in male adoles-
cents. Yet, low birth weight is not associated with blood
lipid levels in female adolescents. Out of the three genes
analyzed, the APOE genotypes seem to be a major deter-
minant factor of lipid and lipoprotein profile in both
sexes. Taken together, these results support the notion
that intrauterine environment interact with genes in deter-
mining blood lipid profile in later life. One possible
explanation to these findings is that a reduced foetal
growth may have negative consequences on the liver
growth. A poor liver growth may cause a down-regulation
of the hepatic receptors, as well as disturbances in the syn-
thesis of cholesterol. Consequently, the influence of the
APOE genotypes on the lipid and lipoprotein metabolism
Table 2: Regression coefficients ( ) showing the association 
between birth weight score and blood lipid and lipoprotein levels 
by sex after controlling for age, pubertal stage, socioeconomic 
status, gestational age, body mass index and cardiorespiratory 
fitness
Males (n = 260) Females (n = 242)
P value P value
TC* 0.035 0.682 0.073 0.476
HDLc* 0.134 0.009 0.058 0.537
LDLc* -0.051 0.549 -0.044 0.668
TG* -0.017 0.841 -0.06 0.541
apoA* 0.187 <0.001 -0.025 0.784
apoB* -0.031 0.723 0.032 0.749
Lp(a)* -0.085 0.334 0.051 0.614
TC-HDLc -0.026 0.76 0.044 0.668
TC/HDLc -0.066 0.003 -0.001 0.991
apoB/apoA -0.113 0.029 0.049 0.609
TC indicates total cholesterol; HDLc, high density liprotein 
cholesterol; LDLc, low density lipoprotein cholesterol; TG, 
triglycerides; Apo, apolipoprotein; Lp(a), lipoprotein a.
*Analyses were performed on log transformed data.
ˆ b
ˆ b ˆ bBMC Medical Genetics 2008, 9:98 http://www.biomedcentral.com/1471-2350/9/98
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would be intensified in those individuals with a low birth
weight.
The potential underlying mechanism linking low birth
weight with and adverse lipid profile in later life remains
unclear. Barker et al. [7] suggested that raised serum TC,
LDLc, and apoB levels in adult life might be associated
with impaired growth during late gestation, when fetal
undernutrition has a disproportionate effect on liver
growth. Therefore, as the liver regulates lipid metabolism,
impaired in utero growth of the liver may program a more
adverse lipid profile.
Interpretation of the birth weight effect on blood lipids
after adjustment for current body size is controversial, and
available results indicate that postnatal changes in size,
rather than fetal growth, is important [35]. Our findings
show that the influence of low birth weight on HDLc,
apoA, TC/HDLc and apoB/apoA in males was not altered
after controlling for any of the measures of current body
size or by others potential confounders such as age [15],
pubertal maturation [27], cardiorespiratory fitness
[14,36] or socioeconomic status [37]. It is noteworthy that
the associations between birth weight and blood lipids
were mainly observed in males. A number of studies have
found evidences for a sex related difference in the pro-
gramming effect of low birth weight and later cardiovas-
cular risk factors [3,38]. Sex related differences in the
association between fetal growth and later coronary heart
disease risk suggest that male fetuses are more vulnerable
to the effects of fetal undernutrition [38]. One of the
explanations lays on the fact that male fetuses seem to
grow at a faster rate than female foetuses [39,40]. There-
fore, assuming that fetal nutritional programming is the
primary pathway for the association between birth weight
and later cardiovascular disease risk factors it could be
expected these associations to be stronger in males com-
pared to females [39,40]. Our results concur with those
showed in a meta-analyses by Lawlor et al. [38]. They
reported that the association between birth weight and
total cholesterol was stronger in males compared to
females. The biological explanation for the different out-
Birth weight score (g) and blood lipid and lipoprotein levels (mg/dl) in male adolescents Figure 1
Birth weight score (g) and blood lipid and lipoprotein levels (mg/dl) in male adolescents. HDLc indicates high den-
sity lipoprotein cholesterol; apo, apolipoprotein; TC, total cholesterol.
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comes obtained in males and females warrant further
investigation. It has been reported that the influence of sex
on genes involved in the lipid and glucose metabolism
could be attributed to hormonal differences [41,42].
However, we did not measure sex hormones, which ham-
per a further study of hormone-lipoprotein relationships
in the studied population.
Variation in blood lipid levels seems to be partially deter-
mined by the APOE genotypes [10], which agree with our
data. APOE genotype has also been shown to affect the
association between birth weight and blood lipids in chil-
dren [10]. Garces et al. reported that a greater effect of the
APOE genotype on TC, LDLc and apoB levels was found
in children with low birth weight [10]. In our study, low
birth weight was associated with higher levels of TC and
LDLc, apoB, and Lp(a) in males with the APOE ε3/ε4 gen-
otype. Likewise, low birth weight was also associated with
higher apoB/apoA ratio, which is a strong cardiovascular
risk factor [43]. This observation suggests that the interac-
tion of APOE genotype and birth weight might be an
important determinant for future atherosclerosis.
Table 3: Lipid and lipoprotein levels (mg/dl), and body mass index (kg/m2) according to the APOE genotypes and sex
Males (n = 260) Females (n = 242)
Genotype ε2/ε3 ε3/ε3 ε3/ε4P  v a l u eε2/ε3 ε3/ε3 ε3/ε4P  v a l u e
n (%) 22 (8.5) 186 (71.6) 52 (19.9) 21 (8.5) 175 (72.6) 46 (18.9)
TC** 144.2* ± 34.4 157.9 ± 24.8 160.6 ± 26.8 <0.05 160.8 ± 24.7 169.1 ± 25.1 177.0 ± 30.8 NS
HDLc** 53.0 ± 8.6 51.4 ± 9.6 49.8 ± 10.3 NS 65.5* ± 11.1 58.6 ± 11.0 58.5 ± 13.1 NS
LDLc** 77.2† ± 28.6 92.7 ± 22.9 95.3 ± 23.8 <0.01 83.2† ± 24.7 97.5 ± 21.9 103.4 ± 26.1 <0.01
TG** 69.7 ± 28.7 69.4 ± 28.1 77.5 ± 39.0 NS 60.4 ± 22.1 64.4 ± 26.1 68.0 ± 30.0 NS
apoA** 115.9 ± 15.6 118.1 ± 17.3 114.5 ± 16.3 NS 141.7† ± 15.6 125.7 ± 17.9 128.9 ± 23.3 <0.01
apoB** 55.6† ± 15.8 68.0 ± 13.0 68.8 ± 16.4 <0.001 59.3† ± 11.7 70.1 ± 12.9 73.9 ± 16.1 <0.001
Lp(a)** 23.1 ± 33.4 31.0 ± 35.1 33.1 ± 41.9 NS 14.3 ± 15.3 33.0 ± 40.3 37.6 ± 38.5 NS
TC-HDLc 91.1* ± 31.6 106.6 ± 24.3 110.8 ± 27.7 <0.01 95.3* ± 25.5 110.4 ± 24.0 118.5 ± 30.5 <0.01
TC/HDLc 2.7* ± 0.7 3.2 ± 0.7 3.4 ± 0.9 <0.01 2.5* ± 0.7 3.0 ± 0.6 3.1 ± 0.8 <0.01
apoB/apoA 0.5* ± 0.1 0.6 ± 0.1 0.6 ± 0.2 <0.01 0.4† ± 0.1 0.6 ± 0.1 0.6 ± 0.2 <0.001
BMI 20.9 ± 3.9 22.2 ± 3.8 22.4 ± 4.0 NS 21.5 ± 3.9 21.7 ± 3.6 21.8 ± 3.4 NS
Values are expressed as mean ± standard deviation, otherwise stated.
P value from ANOVA, adjusted for mass significance.
*P < 0.05; †P < 0.01 for ε2/ε3 vs ε3/ε3 (Tukey test).
TC indicates total cholesterol; HDLc, high density liprotein cholesterol; LDLc, low density lipoprotein cholesterol; TG, triglycerides; Apo, 
apolipoprotein; Lp(a), lipoprotein (a); BMI, body mass index; NS, not significant.
**Analyses were performed on log transformed data, but non-transformed data are presented in the table.
Table 4: Lipid and lipoprotein levels (mg/dl) and body mass index (kg/m2) according to the APOC3 genotypes and sex
Males (n = 260) Females (n = 242)
Genotype S1/S1 S1/S2 P value S1/S1 S1/S2 P value
n (%) 214 (82.1) 46 (17.0) 198 (81.8) 44 (18.2)
TC* 156.2 ± 26.4 159.7 ± 27.0 NS 167.2 ± 25.2 181.9 ± 28.9 <0.001
HDLc* 51.0 ± 9.4 51.1 ± 11.4 NS 59.0 ± 11.4 60.0 ± 12.0 NS
LDLc* 91.1 ± 23.7 93.3 ± 25.2 NS 95.5 ± 22.4 106.3 ± 25.7 NS
TG* 70.5 ± 31.7 76.1 ± 31.3 NS 63.5 ± 26.1 70.6 ± 27.8 NS
apoA* 117.6 ± 17.2 114.1 ± 16.5 NS 127.0 ± 19.5 130.2 ± 18.1 NS
apoB* 66.6 ± 14.4 68.4 ± 14.0 NS 68.8 ± 13.1 74.9 ± 16.1 NS
Lp(a)* 31.2 ± 37.1 27.9 ± 32.4 NS 32.5 ± 39.4 31.8 ± 36.8 NS
TC-HDLc 105.2 ± 25.7 108.6 ± 27.0 NS 108.2 ± 23.9 121.8 ± 31.4 <0.01
TC/HDLc 3.2 ± 0.7 3.3 ± 0.8 NS 2.9 ± 0.6 3.2 ± 0.9 NS
apoB/apoA 0.6 ± 0.1 0.6 ± 0.2 NS 0.6 ± 0.1 0.6 ± 0.2 NS
BMI 22.1 ± 3.9 22.2 ± 3.8 NS 21.5 ± 3.4 22.6 ± 4.0 NS
Values are expressed as mean ± standard deviation, otherwise stated.
P value from ANOVA, adjusted for mass significance.
TC indicates total cholesterol; HDLc, high density liprotein cholesterol; LDLc, low density lipoprotein cholesterol; TG, triglycerides; Apo, 
apolipoprotein; Lp(a), lipoprotein (a); NS, not significant
*Analyses were performed on log transformed data, but non-transformed data are presented in the table.BMC Medical Genetics 2008, 9:98 http://www.biomedcentral.com/1471-2350/9/98
Page 8 of 11
(page number not for citation purposes)
Female adolescents with the APOC3 S1/S2 genotype had
elevated TC and non-HDLc levels, which is in agreement
with another study [44]. The levels of triglyceride were
similar between S1/S1 and S1/S2 genotypes in both males
and females as reported in other population samples
[45,46]. We also found that low birth weight was associ-
ated with lower levels of apoA in males with the APOC3
S1/S1 genotype, whereas low birth weight was associated
with higher levels of Lp(a) in males with both S1/S1 and
S1/S2 genotypes. This is the first study examining the
influence of this polymorphism on the association
between low birth weight and blood lipid levels in adoles-
cents.
The PPARγ2 gene plays an important role in the regula-
tion of glucose, lipid and energy metabolism [47], there-
fore it would be expected that the PPARγ2 genotypes
could affect circulating lipid levels. The findings concern-
ing the associations between PPARγ2 genotypes and lipid
levels are contradictory [11,41,48-50]. We did not find
differences on blood lipid and lipoprotein levels between
genotypes, nor did on birth weight. Pfab et al. reported
Table 5: Regression coefficients ( ) showing the association between birth weight score and lipid and lipoprotein levels by APOE 
genotypes and sex after controlling for age, pubertal stage, socioeconomic status, gestational age, body mass index and 
cardiorespiratory fitness
Males (n = 260) Females (n = 242)
ε2/ε3 ε3/ε3 ε3/ε4 ε2/ε3 ε3/ε3 ε3/ε4
P value P value P value P value P value P value
TC* 0.019 0.976 0.198 0.065 -0.401 0.042 0.787 0.353 0.157 0.197 -0.313 0.262
HDLc* 0.487 0.242 0.285 0.011 0.262 0.238 0.797 0.427 0.153 0.195 0.525 0.027
LDLc* -0.109 0.787 0.121 0.260 -0.622 0.003 0.458 0.566 0.116 0.354 -0.302 0.264
TG* -0.023 0.956 0.001 0.988 0.048 0.824 0.610 0.031 -0.153 0.171 -0.477 0.039
apoA* 0.424 0.326 0.236 0.022 0.328 0.125 0.698 0.314 0.150 0.900 -0.267 0.278
apoB* -0.092 0.820 0.160 0.145 -0.554 0.008 0.428 0.540 -0.172 0.172 -0.076 0.780
Lp(a)* -0.064 0.863 0.122 0.259 -0.625 0.002 -0.301 0.743 0.054 0.667 0.054 0.843
TC-HDLc -0.019 0.663 0.127 0.227 -0.454 0.024 0.518 0.522 0.085 0.501 -0.060 0.816
TC/HDLc -0.402 0.286 0.014 0.889 -0.406 0.028 0.106 0.900 -0.041 0.742 0.243 0.291
apoB/apoA -0.333 0.387 -0.007 0.946 -0.518 0.011 0.142 0.850 0.047 0.699 0.130 0.588
TC indicates total cholesterol; HDLc, high density liprotein cholesterol; LDLc, low density lipoprotein cholesterol; TG, triglycerides; Apo, 
apolipoprotein; Lp(a), lipoprotein a.
*Analyses were performed on log transformed data.
ˆ b
ˆ b ˆ b ˆ b ˆ b ˆ b ˆ b
Table 6: Regression coefficients ( ) showing the association between birth weight score and lipid and lipoprotein levels by APOC3 
genotypes and sex after controlling for age, pubertal stage, socioeconomic status, gestational age, body mass index and 
cardiorespiratory fitness
Males (n = 260) Females (n = 242)
S1/S1 S1/S2 S1/S1 S1/S2
P value P value P value P value
TC* 0.050 0.609 -0.301 0.211 0.032 0.795 -0.309 0.535
HDLc* 0.184 0.053 -0.148 0.493 -0.063 0.590 0.363 0.346
LDLc* -0.089 0.360 -0.208 0.387 -0.002 0.987 -0.305 0.528
TG* 0.048 0.616 -0.190 0.405 0.188 0.113 -0.588 0.227
apoA* 0.244 0.010 -0.146 0.522 -0.120 0.279 0.281 0.456
apoB* -0.043 0.668 -0.267 0.268 0.022 0.859 -0.330 0.469
Lp(a)* -0.294 0.003 -0.731 <0.001 0.021 0.865 0.020 0.867
TC-HDLc 0.022 0.871 -0.278 0.277 0.050 0.682 -0.409 0.394
TC/HDLc -0.086 0.355 -0.087 0.722 0.097 0.407 -0.433 0.338
apoB/apoA -0.144 0.130 -0.166 0.504 0.108 0.351 -0.377 0.367
TC indicates total cholesterol; HDLc, high density liprotein cholesterol; LDLc, low density lipoprotein cholesterol; TG, triglycerides; Apo, 
apolipoprotein; Lp(a), lipoprotein a.
*Analyses were performed on log transformed data.
ˆ b
ˆ b ˆ b ˆ b ˆ bBMC Medical Genetics 2008, 9:98 http://www.biomedcentral.com/1471-2350/9/98
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that neither the fetal nor the maternal PPARγ2 genotypes
affected the birth weight of the 1950 newborn studied
[50]. There is one study underlying the influence of
PPARγ2 genotypes on the association between birth
weight and lipid levels among elderly people [11]. It was
reported that the Ala12 allele was associated with an
increased TC, LDLc, and non-HDLc levels only among
those who had birth weights lower than 3000 g. We did
not find a significant effect of birth weight on lipid levels
regarding the analyzed PPARγ2 genotypes, which agree
with others [50].
Other factors such as current dietary intake may have
affected the lipid levels, but such data were not available
in the AVENA Study. There is controversy about the
influence of age at the onset of menses on lipid and lipo-
protein levels. Yet, no effect of age of menarche on lipid
levels have been observed in the AVENA Study popula-
tion [15]. The inclusion of age of menarche in the analy-
sis rather than pubertal status did not alter the outcome.
Birth weight might be a crude marker of the influence of
maternal environment on fetal development and there-
fore underestimate the influence of such factors on off-
spring health outcomes. Future studies should directly
measure potentially modifiable factors such as maternal
nutrition, smoking, alcohol consumption or exercise,
and relate these to offspring cardiovascular disease risk
factors. It also remains possible that other birth meas-
ures including ponderal index, head circumference of
waist circumference could be more important, but these
measures were not available in the present study. The
results should be interpreted with caution due to the
small sample sizes.
Conclusion
The results of this study suggest that intrauterine environ-
ment interact with the genetic background affecting the
lipid profile in later life. The findings indicate that low
birth weight has a deleterious influence on lipid profile
particularly in adolescents with the APOE ε3/ε4 genotype.
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